Evidence map›Paper›PMID 42892923›Full record

Observational studyResearch and practice in thrombosis and haemostasis2026

Association of dual-pathway antithrombotic therapy with primary patency after iliofemoral venous stenting: a multicenter cohort study.

Can Chen, Zhenyu Guo, Jian Tang, Zhiqing Wei, Guowei Liu, Zhenyu Shi, Daqiao Guo, Weiguo Fu, Qianzhou Lv, Baolei Guo

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Can ChenDepartment of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenyu GuoDepartment of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, Shanghai, China.
Jian TangDepartment of Vascular Surgery, Second People's Hospital of Changshu, Suzhou, Jiangsu Province, China.
Zhiqing WeiDepartment of Vascular Surgery, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.
Guowei LiuDepartment of General Surgery, Shanghai Xuhui District Central Hospital, Shanghai, China.
Zhenyu ShiDepartment of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, Shanghai, China.
Daqiao GuoDepartment of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, Shanghai, China.
Weiguo FuDepartment of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, Shanghai, China.
Qianzhou LvDepartment of Pharmacy, Zhongshan Hospital, Fudan University, Shanghai, China.
Baolei GuoDepartment of Vascular Surgery, Zhongshan Hospital, Institute of Vascular Surgery, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The optimal antithrombotic strategy after iliofemoral venous stenting remains uncertain. Objectives: This study aimed to evaluate the association of dual-pathway antithrombotic therapy with primary patency after iliofemoral venous stenting. Methods: This ambispective, multicenter observational study included consecutive patients who underwent successful iliofemoral venous stent implantation between 2019 and 2024. Patients were categorized according to their postoperative antithrombotic regimen into dual-pathway antithrombotic therapy (anticoagulation plus antiplatelet therapy [AC+APT]) and anticoagulation (AC) alone groups. The primary outcome was primary stent patency. Cox regression was used to identify independent predictors of loss of patency. Results: A total of 247 patients were included, with 145 receiving AC+APT and 102 receiving AC alone. During a median follow-up of 24 months (IQR, 15-38 months), the overall primary patency rate was 91.1%. Primary patency did not differ significantly between the AC+APT and AC groups in the overall cohort (log-rank Conclusion: Primary patency after iliofemoral venous stenting was similarly high with dual-pathway antithrombotic therapy and AC alone. An exploratory analysis suggested a possible association between AC+APT and improved patency in patients with post-thrombotic syndrome. Adequately powered randomized trials with longer follow-up are needed to confirm this finding and assess long-term safety.

Indexed as

AnticoagulantsFemoral VeinFibrinolytic AgentsIliac VeinPlatelet Aggregation InhibitorsPostthrombotic SyndromeStentsAgedFemaleHumansMaleMiddle AgedTreatment OutcomeVascular PatencyAnticoagulantsFibrinolytic AgentsPlatelet Aggregation Inhibitorsanticoagulantsiliac veinplatelet aggregation inhibitorspost-thrombotic syndromestentsvascular patency

Identifiers

PMID42892923
PMCPMC13675916

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.